Abcam has opened a new site in Waltham, MA. The facility is a central part of Abcam’s growth in the US and will serve as a hub for its R&D and commercial activities in the region.
“Abcam’s first step toward global expansion was in 2003 at Kendall Square. Since then, the US has become our largest market,“ commented Alan Hirzel, CEO at Abcam. “Investing in and expanding our presence in the vibrant Greater Boston cluster is another step in our journey to support biopharma partners and life science researchers globally, in their quest to accelerate discovery and the translation of these discoveries into improved human health outcomes.”
Abcam says the site will increase its flexibility, scale, and capacity in R&D, production, distribution, and customer service required to address the increasing needs of the life sciences sector. It believes the ability to provide critical reagents to support research in all areas of the life sciences is vital to enable scientific breakthroughs that underpin the rapid development of diagnostics, vaccines, and potential therapeutics.
“Massachusetts continues to attract life sciences companies from across the globe, who come here to access our leading academic and medical institutions, diverse talent, a supportive government, and a robust start-up community,” said Kendalle Burlin O’Connell, president and COO at MassBio. “We are thrilled to see Abcam outgrow its presence in Kendall Square and expand to Waltham, an area of growing interest for life sciences companies and one that is positioned for explosive growth in the coming years.”
Image credit: Duncan Lake of Cresa
